These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36841501)

  • 1. The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial.
    Chantasrisawad N; Techasaensiri C; Kosalaraksa P; Phongsamart W; Tangsathapornpong A; Jaru-Ampornpan P; Sophonphan J; Suntarattiwong P; Puthanakit T;
    Int J Infect Dis; 2023 May; 130():52-59. PubMed ID: 36841501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster.
    Chantasrisawad N; Puthanakit T; Kornsitthikul K; Jaru-Ampornpan P; Tawan M; Matapituk P; Sophonphan J; Anugulruengkitt S; Tangsathapornpong A; Katanyutanon A;
    Vaccine X; 2022 Dec; 12():100221. PubMed ID: 36213592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents.
    Puthanakit T; Nantanee R; Jaru-Ampornpan P; Chantasrisawad N; Sophonphan J; Meepuksom T; Jupimai T; Sodsai P; Anugulruengkitt S; Hirankarn N;
    Vaccine X; 2022 Dec; 12():100211. PubMed ID: 36059600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance.
    Nantanee R; Jaru-Ampornpan P; Chantasrisawad N; Himananto O; Papakhee S; Sophonphan J; Tawan M; Jupimai T; Anugulruengkitt S; Puthanakit T;
    Vaccine X; 2023 Dec; 15():100367. PubMed ID: 37601322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine.
    Leung NHL; Cheng SMS; Martín-Sánchez M; Au NYM; Ng YY; Luk LLH; Chan KCK; Li JKC; Leung YWY; Tsang LCH; Chaothai S; Kwan KKH; Ip DKM; Poon LLM; Leung GM; Peiris JSM; Cowling BJ
    Clin Infect Dis; 2023 Feb; 76(3):e299-e307. PubMed ID: 35675370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents.
    Assavavongwaikit P; Chantasrisawad N; Himananto O; Phasomsap C; Klawaja P; Cartledge S; Nadsasarn R; Jupimai T; Kawichai S; Anugulruengkitt S; Puthanakit T; On Behalf Of The Study Team
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Omicron Infection and Changes in Serum Antibody Response to Wild-Type, Delta, and Omicron After a Booster Dose With BNT163b2 Vaccine in Korean Healthcare Workers.
    Lim SH; Kim HJ; Kim SH; Choi SH; Kim B; Kim JY; Ji YS; Kim T; Choo EJ; Jung JC; Moon JE; Kim CK; Park SK; Yun J
    J Korean Med Sci; 2023 Apr; 38(13):e103. PubMed ID: 37012688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BNT162b2 vaccine induced variant-specific immunity, safety and risk of Omicron breakthrough infection in children aged 5 to 11 years: a cohort study.
    Yung CF; Le Bert N; Kam KQ; Saffari SE; Tan CW; Mah YY; Zhang J; Yeoh AY; Zhu F; Hariharaputran S; Chong CY; Bertoletti A; Wang L
    Sci Rep; 2023 Oct; 13(1):17337. PubMed ID: 37833554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a biotin-based surrogate virus neutralization test for detecting postvaccination antibodies against SARS-CoV-2 variants in sera.
    Ahn MJ; Kang JA; Hong SM; Lee KS; Kim DH; Song D; Jeong DG
    Biochem Biophys Res Commun; 2023 Feb; 646():8-18. PubMed ID: 36696754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
    Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
    JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
    Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
    Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents.
    Puthanakit T; Chantasrisawad N; Yoohat K; Nantanee R; Sophonphan J; Meepuksom T; Sodsai P; Phanthanawiboon S; Jantarabenjakul W; Hirankarn N; Kosalaraksa P
    Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity.
    Bae S; Ko JH; Choi JY; Park WJ; Lim SY; Ahn JY; Song KH; Lee KH; Song YG; Chan Kim Y; Park YS; Choi WS; Jeong HW; Kim SW; Kwon KT; Kang ES; Kim AR; Jang S; Kim B; Kim SS; Jang HC; Choi JY; Kim SH; Peck KR
    Clin Microbiol Infect; 2022 Oct; 28(10):1390.e1-1390.e7. PubMed ID: 35598855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Nanthapisal S; Puthanakit T; Jaru-Ampornpan P; Nantanee R; Sodsai P; Himananto O; Sophonphan J; Suchartlikitwong P; Hiransuthikul N; Angkasekwinai P; Tangsathapornpong A; Hirankarn N;
    Vaccine; 2022 Apr; 40(18):2551-2560. PubMed ID: 35341647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222.
    Nantanee R; Jantarabenjakul W; Jaru-Ampornpan P; Sodsai P; Himananto O; Athipunjapong J; Sophonphan J; Nanthapisal S; Hirankarn N; Puthanakit T;
    Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants.
    Belik M; Jalkanen P; Lundberg R; Reinholm A; Laine L; Väisänen E; Skön M; Tähtinen PA; Ivaska L; Pakkanen SH; Häkkinen HK; Ortamo E; Pasternack A; Ritvos MA; Naves RA; Miettinen S; Sironen T; Vapalahti O; Ritvos O; Österlund P; Kantele A; Lempainen J; Kakkola L; Kolehmainen P; Julkunen I
    Nat Commun; 2022 May; 13(1):2476. PubMed ID: 35513437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
    Shaw RH; Liu X; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dejnirattisai W; Dinesh T; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Morey ER; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet Respir Med; 2022 Nov; 10(11):1049-1060. PubMed ID: 35690076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid immunity from SARS-CoV-2 infection and mRNA BNT162b2 vaccine among Thai school-aged children.
    Saraban K; Suntarattiwong P; Chantasrisawad N; Boonsathorn S; Kosalaraksa P; Phongsamart W; Tangsathapornpong A; Jaruampornpan P; Srisarang S; Puthanakit T;
    Vaccine X; 2023 Dec; 15():100414. PubMed ID: 38090644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.